Advertisement

IL-22 in hepatocyte’s survival of Pakistani patients with end stage liver disease: an insight into IL 22 mediated hepato-regenerative pathway

  • Muhammad Saalim
  • Saleha Resham
  • Sobia ManzoorEmail author
  • Hassam Ahmad
  • Tariq Ali Bangash
  • Amir Latif
  • Shahla Jaleel
Original Article
  • 24 Downloads

Abstract

Hepatitis is the principal cause of hepatocellular carcinoma (HCC) and decompensated cirrhosis. HCC is amongst the leading causes of deaths worldwide. Current therapeutic options have proven to be unsuccessful in treating this disease due to multifactorial nature of the disease. The present study was designed to investigate the role of IL-22 mediated survival of hepatocytes during cirrhosis and HCC. Resected/explanted liver tissue samples of patients with End Stage Liver Disease were obtained from Hepato-Pancreato-Biliary Liver Transplant Unit of Sheikh Zayed Hospital, Lahore, Pakistan. Qualitative expression of IL-22, SOCS3, and IL-22 induced anti-apoptotic protein, B-cell lymphoma extra-large (Bcl-xL), were evaluated by Immunohistochemical analysis (IHC). The IHC analysis revealed significantly high expression of IL-22, SOCS3, and Bcl-xL within explanted livers of HCC patients. Overall, the expression of SOCS3 was higher than any other protein, and the expression of all proteins showed significant variation in different group of patients based on clincopathological features. The results of the current study indicated that IL-22 mediated JAK-STAT pathway i.e. liver regeneration and healing is dependent on the disease progression and type of agent responsible for causing the infection in the first place. However, quantitative analysis of these factors in future can provide further evidence of the role of this pathway in HCC for development of anti-HCC therapies.

Keywords

HCC IL-22 Immunohistochemistry Liver regeneration 

Notes

Author contributions

MS and SR planned, carried the research and wrote the manuscript under the supervision and guidance of SM. HA, TAB and AL provided the samples, and gave basic input regarding transplant procedure and sample preservation. SJ provided the independent analysis of IHC.

Supplementary material

11033_2018_4573_MOESM1_ESM.docx (24 kb)
Supplementary material 1 (DOCX 23 KB)

References

  1. 1.
    Ali SA, Donahue RM, Qureshi H, Vermund SH (2009) Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. Int J Infect Dis 13:9–19CrossRefGoogle Scholar
  2. 2.
    Bantel H, Schulze-Osthoff K (2003) Apoptosis in hepatitis C virus infection. Cell Death Differ 10:S48–S58CrossRefGoogle Scholar
  3. 3.
    Byron D, Minuk GY (1996) Clinical hepatology: profile of an urban, hospital-based practic Hepatology 24:813–815CrossRefGoogle Scholar
  4. 4.
    Cancer IAfRo (1989) Diesel and gasoline engine exhausts and some nitroarenes/this publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans which met in Lyon, 1–8 March 1988Google Scholar
  5. 5.
    Cella M et al (2008) A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 457:722–725CrossRefGoogle Scholar
  6. 6.
    Chan K-M, Yu M-C, Chou H-S, Wu T-J, Lee C-F, Lee W-C (2011) Significance of tumor necrosis for outcome of patients with hepatocellular carcinoma receiving locoregional therapy prior to liver transplantation. Ann Surg Oncol 18:2638–2646CrossRefGoogle Scholar
  7. 7.
    Cobleigh MA, Robek MD (2013) Protective and pathological properties of IL-22 in liver disease: implications for viral hepatitis. Am J Pathol 182:21–28CrossRefGoogle Scholar
  8. 8.
    Debruyne EN, Delanghe JR (2008) Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta 395:19–26CrossRefGoogle Scholar
  9. 9.
    Du G-J, Lin H-H, Xu Q-T, Wang M-W (2006) Bcl-2 switches the type of demise from apoptosis to necrosis via cyclooxygenase-2 upregulation in HeLa cell induced by hydrogen peroxide. Cancer Lett 232:179–188CrossRefGoogle Scholar
  10. 10.
    Dumoutier L, de Meester C, Tavernier J, Renauld J-C (2009) New activation modus of STAT3 A tyrosine-less region of the interleukin-22 receptor recruits STAT3 by interacting with its coiled-coil domain. J Biol Chem 284:26377–26384CrossRefGoogle Scholar
  11. 11.
    Dumoutier L, Louahed J, Renauld J-C (2000) Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol 164:1814–1819CrossRefGoogle Scholar
  12. 12.
    El-Serag HB, Davila JA, Petersen NJ, McGlynn KA (2003) The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139:817–823CrossRefGoogle Scholar
  13. 13.
    El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576CrossRefGoogle Scholar
  14. 14.
    Farrell GC (2003) Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia–Pacific region? J Gastroenterol Hepatol 18:124–138CrossRefGoogle Scholar
  15. 15.
    Feng D et al (2012) Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection. Gastroenterology 143:188–198.e187CrossRefGoogle Scholar
  16. 16.
    Ferlay J et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386CrossRefGoogle Scholar
  17. 17.
    Foster RG, Golden-Mason L, Rutebemberwa A, Rosen HR (2012) Interleukin (IL)-17/IL-22-producing T cells enriched within the liver of patients with chronic hepatitis C viral (HCV) infection. Dig Dis Sci 57:381–389CrossRefGoogle Scholar
  18. 18.
    Fujita H, Nograles KE, Kikuchi T, Gonzalez J, Carucci JA, Krueger JG (2009) Human Langerhans cells induce distinct IL-22-producing CD4 + T cells lacking IL-17 production. Proc Natl Acad Sci 106:21795–21800CrossRefGoogle Scholar
  19. 19.
    Hennig BJ et al (2007) Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection. Liver Int 27:1134–1143CrossRefGoogle Scholar
  20. 20.
    Huang DC, O’Reilly LA, Strasser A, Cory S (1997) The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J 16:4628–4638CrossRefGoogle Scholar
  21. 21.
    Imaoka S et al (1994) Necrosis of hepatocellular carcinoma caused by spontaneously arising arterial thrombus. Hepato-gastroenterology 41:359–362Google Scholar
  22. 22.
    Jiang R et al (2011) Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 54:900–909CrossRefGoogle Scholar
  23. 23.
    Knoll S, Fürst K, Thomas S, Villanueva Baselga S, Stoll A, Schaefer S, Pützer BM (2011) Dissection of cell context-dependent interactions between HBx and p53 family members in regulation of apoptosis: a role for HBV-induced. HCC Cell Cycle 10:3554–3565CrossRefGoogle Scholar
  24. 24.
    Kong X, Feng D, Wang H, Hong F, Bertola A, Wang FS, Gao B (2012) Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology 56:1150–1159CrossRefGoogle Scholar
  25. 25.
    Kronenberger B et al (2012) Interleukin-22 predicts severity and death in advanced liver cirrhosis: a prospective cohort study. BMC Med 10:102CrossRefGoogle Scholar
  26. 26.
    Liang SC, Tan X-Y, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA (2006) Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203:2271–2279CrossRefGoogle Scholar
  27. 27.
    Ludwig J, Viggiano TR, Mcgill DB, Oh B (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 7:434–438Google Scholar
  28. 28.
    Marmot M et al (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. American Institute for Cancer Research, Washington, DCGoogle Scholar
  29. 29.
    Mazel S, Burtrum D, Petrie HT (1996) Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. J Exp Med 183:2219–2226CrossRefGoogle Scholar
  30. 30.
    Michels J, Kepp O, Senovilla L, Lissa D, Castedo M, Kroemer G, Galluzzi L (2013) Functions of BCL-X L at the interface between cell death and metabolism. Int J Cell Biol.  https://doi.org/10.1155/2013/705294 Google Scholar
  31. 31.
    Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA (2002) Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 963:13–20CrossRefGoogle Scholar
  32. 32.
    Nagalakshmi ML, Rascle A, Zurawski S, Menon S, de Waal Malefyt R (2004) Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int Immunopharmacol 4:679–691CrossRefGoogle Scholar
  33. 33.
    Pan H, Hong F, Radaeva S, Gao B (2004) Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell Mol Immunol 1:43–49Google Scholar
  34. 34.
    Park O et al (2011) In vivo consequences of liver-specific interleukin-22 expression in mice: implications for human liver disease progression. Hepatology 54:252–261CrossRefGoogle Scholar
  35. 35.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA: Cancer J Clin 55:74–108Google Scholar
  36. 36.
    Pierce RH, Vail ME, Ralph L, Campbell JS, Fausto N (2002) Bcl-2 expression inhibits liver carcinogenesis and delays the development of proliferating foci. Am J Pathol 160:1555–1560CrossRefGoogle Scholar
  37. 37.
    Poon D et al (2009) Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10:1111–1118CrossRefGoogle Scholar
  38. 38.
    Qin S, Ma S, Huang X, Lu D, Zhou Y, Jiang H (2014) Th22 cells are associated with hepatocellular carcinoma development and progression. Chin J Cancer Res 26:135Google Scholar
  39. 39.
    Radaeva S, Sun R, Pan H, Hong F, Gao B (2004) Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39:1332–1342CrossRefGoogle Scholar
  40. 40.
    Ren X, Hu B, Colletti LM (2010) IL-22 is involved in liver regeneration after hepatectomy. Am J Physiol-Gastrointest Liver Physiol 298:G74–G80CrossRefGoogle Scholar
  41. 41.
    Sanjabi S, Zenewicz LA, Kamanaka M, Flavell RA (2009) Anti-inflammatory and pro-inflammatory roles of TGF-β, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol 9:447–453CrossRefGoogle Scholar
  42. 42.
    Sanyal AJ, Yoon SK, Lencioni R (2010) The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 15:14–22CrossRefGoogle Scholar
  43. 43.
    Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, Thompson CB, Tsujimoto Y (2004) Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol 6:1221–1228CrossRefGoogle Scholar
  44. 44.
    Thorgeirsson SS, Grisham JW (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31:339–346CrossRefGoogle Scholar
  45. 45.
    Tsamandas AC et al (2003) Potential role of bcl-2 and bax mRNA and protein expression in chronic hepatitis type B and C: a clinicopathologic study. Mod Pathol 16:1273–1288CrossRefGoogle Scholar
  46. 46.
    Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K (2009) Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 44:102–107CrossRefGoogle Scholar
  47. 47.
    Vail ME, Pierce RH, Fausto N (2001) Bcl-2 delays and alters hepatic carcinogenesis induced by transforming growth factor α. Cancer Res 61:594–601Google Scholar
  48. 48.
    Watanabe J, Kushihata F, Honda K, Mominoki K, Matsuda S, Kobayashi N (2002) Bcl-xL overexpression in human hepatocellular carcinoma. Int J Oncol 21:515–519Google Scholar
  49. 49.
    Wong R, Corley DA (2008) Racial and ethnic variations in hepatocellular carcinoma incidence within the United States The American. J Med 121:525–531CrossRefGoogle Scholar
  50. 50.
    Xiang X, Gui H, King NJ, Cole L, Wang H, Xie Q, Bao S (2012) IL-22 and non-ELR-CXC chemokine expression in chronic hepatitis B virus-infected liver. Immunol Cell Biol 90:611–619CrossRefGoogle Scholar
  51. 51.
    Yang JD, Roberts LR (2010) Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 7:448–458CrossRefGoogle Scholar
  52. 52.
    Yoshimura A, Naka T, Kubo M (2007) SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 7:454–465CrossRefGoogle Scholar
  53. 53.
    Yuen MF, Hou JL, Chutaputti A (2009) Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 24:346–353CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Atta-ur-Rehman School of Applied Bio-Sciences, Department of Healthcare BiotechnologyNational University of Sciences and TechnologyIslamabadPakistan
  2. 2.Hepato-Pancreato-Biliary Liver Transplant UnitShaikh Zayed HospitalLahorePakistan
  3. 3.Department of HistopathologyShaikh Zayed HospitalLahorePakistan

Personalised recommendations